At a novel Oncologic Drugs Advisor...
At a novel Oncologic Drugs Advisory Committee (ODAC) meeting, the sum of two units anticancer drugs under review were not approveed to be approved with their existing clinical trial information. The ODAC recommendation is just a suggestion to the FDA for its ultimate decision about the couple New Drug Applications, on the other hand one that is often followed. The couple drugs in question were Allos Therapeutics' (Westminster, CO) RSR13 (efaproxiral) and Aventis (Strasbourg, France)/Genta's (Berkeley Heights, NJ) Genasense (oblimersen sodium). RSR13 did not
|